Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial (Q38882536)
Jump to navigation
Jump to search
scientific article published on 5 April 2016
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial |
scientific article published on 5 April 2016 |
Statements
1 reference
Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial (English)
1 reference
1 reference
Isabelle Ray-Coquard
1 reference
Nicolas Isambert
1 reference
Florence Duffaud
1 reference
François Bertucci
1 reference
Emmanuelle Bompas
1 reference
Maud Toulmonde
1 reference
Olivier Bouché
1 reference
Claire Cropet
1 reference
Mathieu Molimard
1 reference
Philippe Cassier
1 reference
Antoine Adenis
1 reference
David Pérol
1 reference
Maria Rios
1 reference
Antoine Italiano
1 reference
Emmanuelle Chauzit
1 reference
Julien Gautier
1 reference
PAZOGIST study group of the French Sarcoma Groupe-Groupe d'Etude des Tumeurs Osseuses (GSF-GETO)
1 reference
5 April 2016
1 reference
1 reference
Identifiers
1 reference